The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•14 April 2026•

1 min read

Genmab’s DARZALEX Sales Reach $3.96 Billion in Q1 2026

Key Facts

1Worldwide net trade sales of DARZALEX totaled USD 3,964 million in the first quarter of 2026.

2Sales reached USD 2,208 million in the U.S. and USD 1,756 million in the rest of the world.

Genmab A/S reported that worldwide net trade sales for its blockbuster drug DARZALEX reached USD 3,964 million in the first quarter of 2026. The performance was driven by strong demand in the United States, where sales hit USD 2,208 million, complemented by USD 1,756 million from international markets. These figures serve as the basis for royalty revenue calculations for Genmab, which receives payments from Johnson & Johnson based on global commercial performance. The drug continues to be a primary revenue driver for the company under its partnership with Janssen Biotech. Analysts view these robust sales figures as a positive indicator for Genmab’s financial health and royalty-based business model. Investors will likely weigh these results against quarterly estimates to determine the near-term trajectory for GMAB and JNJ shares.